United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefotetan disodium (unii: 0gxp746vxb) (cefotetan - unii:48spp0pa9q) - cefotetan 1 g in 10 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotetan and other antibacterial drugs, cefotetan should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefotetan for injection, usp is indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms: urinary tract infections caused by e. coli, klebsiella spp (including k. pneumoniae ), proteus mirabilis , proteus vulgaris , providencia rettgeri , and morganella morganii ). lower respiratory tract infections caused by streptococcus pneumoniae , staphylococcus aureus (methicillin-susceptible), haemophilus influenzae

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - cefotetan disodium (unii: 0gxp746vxb) (cefotetan - unii:48spp0pa9q) - cefotetan 1 g in 10 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotan® and other antibacterial drugs, cefotan® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefotan® (cefotetan for injection, usp) is indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms: urinary tract infections caused by e. coli, klebsiella spp (including k. pneumoniae ), proteus mirabilis, proteus

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - cefotetan disodium (unii: 0gxp746vxb) (cefotetan - unii:48spp0pa9q) - cefotetan 1 g in 50 ml - cefotetan for injection and dextrose injection is indicated for the treatment of urinary tract infections caused by e. coli , klebsiella spp (including k. pneumoniae ), proteus mirabilis , proteus vulgaris , providencia rettgeri , and morganella morganii . cefotetan for injection and dextrose injection is indicated for the treatment of lower respiratory tract infections caused by streptococcus pneumoniae , staphylococcus aureus (methicillin susceptible), haemophilus influenzae , klebsiella species (including k. pneumoniae ), e. coli , proteus mirabilis , and serratia marcescens . cefotetan for injection and dextrose injection is indicated for the treatment of skin and skin structure infections due to staphylococcus aureus (methicillin susceptible), staphylococcus epidermidis (methicillin susceptible), streptococcus pyogenes , streptococcus species, escherichia coli , klebsiella pneumoniae , peptococcus niger , peptostreptococcus species. cefotetan for injection and dextrose injection is indicated for t

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefotetan disodium (unii: 0gxp746vxb) (cefotetan - unii:48spp0pa9q) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotetan and other antibacterial drugs, cefotetan should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefotetan for injection, usp is indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms: urinary tract infections caused by e. coli, klebsiella spp (including k. pneumoniae ), proteus mirabilis and proteus spp (which may include the organisms now called proteus vulgaris , providencia rettgeri , and morganella morganii ). lower respiratory tract infections caused by streptococcus pneumoniae , staphyloco

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals, lp - cefotetan disodium (unii: 0gxp746vxb) (cefotetan - unii:48spp0pa9q) - injection, solution - 1 g in 50 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotan and other antibacterial drugs, cefotan should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefotan is indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms: cefotetan, like other cephalosporins, has no activity against chlamydia trachomatis . therefore, when cephalosporins are used in the treatment of pelvic inflammatory disease, and c. trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. *efficacy for this organism in this organ system was studied in fewer tha

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefotetan (unii: 48spp0pa9q) (cefotetan - unii:48spp0pa9q) - cefotetan 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotetan and other antibacterial drugs, cefotetan should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   cefotetan for injection, usp is indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms: urinary tract infections caused by e. coli , klebsiella spp (including k. pneumoniae ), proteus mirabilis and proteus spp (which may include the organisms now called proteus vulgaris , providencia rettgeri , and morganella morganii ). lower respiratory tract infections caused by streptococcus pneumoniae , staphylococcus a

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - cefotetan disodium 1 g - powder for injection - 1 g - active: cefotetan disodium 1 g

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - cefotetan disodium 2 g - powder for injection - 2 g - active: cefotetan disodium 2 g

Canada - English - Health Canada

wyeth canada - cefotetan (cefotetan disodium) - powder for solution - 1g - cefotetan (cefotetan disodium) 1g - cephamycins

Canada - English - Health Canada

wyeth canada - cefotetan (cefotetan disodium) - powder for solution - 2g - cefotetan (cefotetan disodium) 2g - cephamycins